Results 51 to 60 of about 2,875 (114)

Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not? [PDF]

Alzheimers Dement
Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete.
Exalto L, van Alphen J, Barkhof F, Teunissen C, Vijverberg E, Aarsland D, Lemstra A.   +6 more
europepmc   +2 more sources

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine
Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the disease ...
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
doaj   +1 more source

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease

Biomedicines
Alzheimer’s Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of amyloid beta1-40 and 1-42, and intracellular ...
Xiaoming Qi, Damir Nizamutdinov, Song Stephen Yi, Erxi Wu, Jason H. Huang   +4 more
doaj   +1 more source

Perspective: Minimally clinically important “symptomatic” benefit associated with disease modification resulting from anti‐amyloid immunotherapy

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Despite some skepticism regarding the amyloid hypothesis, there is growing evidence that clearing amyloid by targeting specific species of amyloid (plaque, oligomers, fibrils, and protofibrils) for removal has therapeutic benefits. Specifically, there is
John Alam, Marwan N. Sabbagh
doaj   +1 more source

Alzheimer’s Disease in the Context of an Aging Society: Challenges and Future Directions

Journal of Education, Health and Sport
Alzheimer’s disease (AD) remains the most prevalent form of dementia and a pressing public health concern, particularly in the context of global population aging.
Aleksandra Boral, Bartłomiej Czarnecki, Wiktoria Pniok, Julia Koczur, Wiktor Werenkowicz, Dominika Kryś, Joanna Brzoza, Michał Górski, Wojciech Kurkiewicz   +8 more
doaj   +1 more source

Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer’s disease: a systematic review and network meta-analysis

Frontiers in Neuroscience
BackgroundThe management of Alzheimer’s disease has shifted toward disease-modifying therapies aimed at delaying disease progression rather than focusing solely on symptomatic treatment.
Shiyu Liu, Shiyu Liu, Min Zhao, Min Zhao, Yuan Liu, Yuan Liu, Xin Yang, Xin Yang, Huayu Yan, Huayu Yan, Hongcai Xu, Hongcai Xu, Yabo Wu, Yabo Wu, Yumin Xu, Yumin Xu   +15 more
doaj   +1 more source

Pharmacological Management of Mild Cognitive Impairment: From Symptomatic Treatment to Disease Modification—A Narrative Review

NeuroSci
Mild cognitive impairment (MCI) is a nosological entity that requires special attention from a therapeutic perspective, because annual conversion rates to dementia of 5–15% in these cases are considered typical.
Andrei Gabriel Mangalagiu, Bogdan Mircea Petrescu, Sorin Riga, Octavian Vasiliu   +3 more
doaj   +1 more source

Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's disease (AD) will benefit more patients.
Hugo Geerts, Silke Bergeler, Mike Walker, Rachel H. Rose, Piet H. van derGraaf   +4 more
doaj   +1 more source

Lecanemab for mild Alzheimer disease – is there a way forward?

Drugs in Context
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab ...
Rajesh R Tampi
doaj   +1 more source

Efficacy and Safety of Recently Approved Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Meta-Analysis

International Journal of Medical Students
Background Alzheimer's disease (AD) is the leading cause of dementia worldwide and affects over 55 million people.  Lecanemab and donanemab are anti-amyloid monoclonal antibodies that flag the abnormal amyloid-beta plaques for removal by the ...
Hassan Khalid, Mohammed Murtada
doaj